You searched for "prevention"

2734 results found

Daflon – a new way to treat idiopathic epistaxis

Epistaxis is a common ENT emergency and most cases are idiopathic. Flavonoids are natural substances with variable phenolic structures that are found in fruit and vegetables and take effect on blood vessels. Daflon is proposed to control epistaxis by “improving...

Systemic steroid therapy for reduction of macrophage migration inhibition factor in the control of nasal polyposis

It is believed that macrophage migration inhibitory factor mediates inflammation by stimulating the release of other pro-inflammatory cytokines. The use of systemic steroids in control of nasal polyposis is an established treatment. In this study the authors have aimed at...

Sinus implants to treat recalcitrant polyps

It is well established that the burden of chronic rhinosinusitis on healthcare costs and patients’ quality of life is high, and that current mainstream treatment options of oral or topical steroids are not without problems. This paper compares two RCTSs...

The septum and breathing

The authors compared the improvement in nasal obstructive symptoms in two groups of patients. One group underwent septoplasty alone and the other septoplasty accompanied with compensatory turbinoplasty. They used the Nasal Obstruction Symptom Evaluation (NOSE) [12] and visual analog scale...

Does minimally invasive surgery under local anaesthesia have a role in the management of chronic rhinusinusitis?

A formal FESS procedure usually done under local anaesthesia is considered as gold standard in the management of chronic rhinusinusitis. However, success is hampered by a significant recurrence rate of polyps requiring revision surgery, long waiting lists, reluctance of elderly...

Can we predict how much benefit patients will get from ESS with a novel monoclonal antibody

Mepolizumab (Nucala) is a humanised IgG1 monoclonal antibody that acts as an IL-5 antagonist. It has been shown to be highly effective in treating severe asthma. It is hypothesised that it will be effective for patients with recalcitrant CRSwNP. This...

A new era in the treatment of recalcitrant nasal polyps?

Chronic rhinosinusitis with nasal polyps (CRSwNP) can be difficult to treat effectively in patients with aggressive or recalcitrant disease. Omalizumab (Xolair) is a monoclonal anti-IgE antibody with proven benefits for patients with moderate/severe asthma and CRSwNP, but this study looks...

When to operate on a patient without chronic disease?

As ENT surgeons, we spend a lot of time managing chronic rhinosinusitis, so a review and update on the management of the acute disease is always helpful. The standard medical treatment of antibiotics, nasal steroids and nasal decongestants are reported...

Tympanometry with cochlear implants

Multifrequency and multicomponent tympanometry enables evaluation of minute changes in the middle ear system as well as changes in resonant frequency. Change in resonant frequency would indicate a change in the natural characteristics of the middle ear, such as mass...

Audiology in this issue...New Landscapes in Audiology

Keiran Joseph, Clinical Lead, Evelina London, Children & Young People’s Audiology Centre, Guy’s & St Thomas’ NHS Foundation Trust, UK. E: Keiran.Joseph@gstt.nhs.uk Over the past year, the world of audiology has changed faster than ever before. The COVID-19 pandemic has...

Breaking the menstrual and menopause taboo

The impact of menstruation and menopause on doctors and surgeons is the subject of a provocative new podcast. As ENT & Audiology News reported in July 2021, WENTS & Friends is a mouthpiece for Women in ENT Surgery UK, an organisation aiming to support women in all stages of training. The third episode lifts the lid on the lack of care, provision and policy for this central aspect of women’s health.

Cochlear implantation in asymmetric hearing loss

Criteria for cochlear implantation (CI) is a constant topic of debate. The UK traditionally had relatively restrictive guidance, although this has been greatly improved by more recent guidance released in 2019. Nevertheless, because of the lack of evidence for cost-effectiveness,...